The Latest Cardiac and Vascular News
NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key […]
Pivotal U.S. and Canada STAR-T Trial enrollment enters the last third of the study. Strong customer demand from Q4 2022 continued into Q1 2023, with current expectation of overall sales growth in 2023 PRINCETON, N.J., May 02, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening […]
NORRISTOWN, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc., is happy to announce that results of the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV™) in patients with severe aortic stenosis will be presented at the upcoming EuroPCR 2023 Conference. EuroPCR is an annual, world-leading conference on interventional cardiovascular […]
Partnership Reinforces USHV’s Position as a Leading Cardiovascular Practice Management Organization and Will Drive Efforts to Transform How Quality Cardiovascular Care Is Delivered NASHVILLE, Tenn.–(BUSINESS WIRE)–US Heart & Vascular (“USHV”), a leading national provider of support services to cardiovascular physician practices, announced today that it has entered into an agreement […]
HeartBeam to Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Funding to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones, Extends Cash Runway into Late 2024 HeartBeam to Host Conference Call to Discuss Financing, Strategic Initiatives and First Quarter 2023 […]
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its Combined Annual Shareholders Meeting was held on May 2, 2023 at Espace Encan, La Rochelle, under […]
Leading Cardiothoracic Surgeon Joins Leadership Team as the Company Leverages its Proprietary nsPFA™ Technology for the Treatment of Atrial Fibrillation HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial […]
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first […]
The recognition comes on the heels of major achievements in the past year, including 5 FDA 510(k) clearances, the Frost & Sullivan Global Technology Innovation Leadership Award, and nearly 10 million patient scans SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the global leader in using AI to combat life-threatening vascular and neurovascular conditions […]
Study will evaluate the safety and efficacy of Vivasure’s PerQseal Closure Device System designed for large arteriotomies GALWAY, Ireland–(BUSINESS WIRE)–Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced it has enrolled the first patients in the company’s PerQseal® PATCH Clinical Study, a multi-center, single-arm, pivotal […]
